{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:34:31Z","timestamp":1790739271986,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011305","name":"UAB | Comprehensive Cancer Center, University of Alabama at Birmingham","doi-asserted-by":"publisher","award":["5P30CAO13148-47"],"award-info":[{"award-number":["5P30CAO13148-47"]}],"id":[{"id":"10.13039\/100011305","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA294647"],"award-info":[{"award-number":["1R01CA294647"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis and limited therapeutic options. In a previous publication, our group defined some of the mechanisms that vitamin D analogue paricalcitol (P) and hydroxychloroquine (H) potentiated the effects of gemcitabine-based chemotherapy in PDAC. Based on this, we hypothesized that PH may potentiate 5-fluorouracil (5FU) and Oxaliplatin-based chemotherapy, and this may involve a novel mechanism of extracellular matrix (ECM) modulation. The combination of PH with 5FU+Oxaliplatin significantly increased the cell death, apoptosis, and S-phase cell cycle arrest as compared to untreated or 5FU\u2009+\u2009Oxaliplatin-treated MIA PaCa-2, HPAC and KPC cell lines. In vivo, the combination therapy inhibited PDAC growth and altered the immune landscape by activating T and NK cells. Proteomic analysis revealed significant reduction in ECM proteins, specifically integrin beta-4 (ITGB4). Confirmation of the role of ITGB4 was performed through genetic knockdown of ITGB4, which led ECM inhibition. In conclusion, the combination of PH significantly enhances the efficacy of Oxaliplatin and 5FU. We identified a new mechanism of action of PH through inhibiting ITGB4, leading to ECM modulation. These results suggest that the combination of PH with cytotoxic chemotherapy should be tested in PDAC clinical trials.<\/jats:p>","DOI":"10.1038\/s41417-025-00967-9","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:32:23Z","timestamp":1758972743000},"page":"1330-1340","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Paricalcitol and hydroxychloroquine modulates extracellular matrix and enhance chemotherapy efficacy in pancreatic cancer"],"prefix":"10.1038","volume":"32","author":[{"given":"Dhana Sekhar Reddy","family":"Bandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujith","family":"Sarvesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Foote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Welsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changde","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Akce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4989-5234","authenticated-orcid":false,"given":"Ganji Purnachandra","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0405-5503","authenticated-orcid":false,"given":"Bassel F.","family":"El-Rayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"967_CR1","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41419-021-03996-y","volume":"12","author":"J Du","year":"2021","unstructured":"Du J, Wang X, Li Y, Ren X, Zhou Y, Hu W, et al. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism. Cell Death Dis. 2021;12:705.","journal-title":"Cell Death Dis"},{"key":"967_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"967_CR3","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1002\/mco2.216","volume":"4","author":"HC Kung","year":"2023","unstructured":"Kung HC, Yu J. Targeted therapy for pancreatic ductal adenocarcinoma: mechanisms and clinical study. MedComm. 2023;4:e216.","journal-title":"MedComm"},{"key":"967_CR4","doi-asserted-by":"publisher","first-page":"9297","DOI":"10.3748\/wjg.v21.i31.9297","volume":"21","author":"A Cid-Arregui","year":"2015","unstructured":"Cid-Arregui A, Juarez V. Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol. 2015;21:9297.","journal-title":"World J Gastroenterol"},{"key":"967_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22490-9","volume":"12","author":"C Tian","year":"2021","unstructured":"Tian C, Huang Y, Clauser KR, Rickelt S, Lau AN, Carr SA, et al. Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens produced selectively by tumor cells. Nat Commun. 2021;12:2328.","journal-title":"Nat Commun"},{"key":"967_CR6","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1158\/1541-7786.MCR-18-1352","volume":"17","author":"S Jin","year":"2019","unstructured":"Jin S, Lee W-C, Aust D, Pilarsky C, Cordes N. \u03b28 integrin mediates pancreatic cancer cell radiochemoresistance. Mol Cancer Res. 2019;17:2126\u201338.","journal-title":"Mol Cancer Res"},{"key":"967_CR7","doi-asserted-by":"publisher","first-page":"19609","DOI":"10.1073\/pnas.1908626116","volume":"116","author":"C Tian","year":"2019","unstructured":"Tian C, Clauser KR, \u00d6hlund D, Rickelt S, Huang Y, Gupta M, et al. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc Natl Acad Sci USA. 2019;116:19609\u201318.","journal-title":"Proc Natl Acad Sci USA"},{"key":"967_CR8","doi-asserted-by":"publisher","first-page":"11008","DOI":"10.1021\/acsnano.9b02395","volume":"13","author":"A Zinger","year":"2019","unstructured":"Zinger A, Koren L, Adir O, Poley M, Alyan M, Yaari Z, et al. Collagenase nanoparticles enhance the penetration of drugs into pancreatic tumors. ACS Nano. 2019;13:11008\u201321.","journal-title":"ACS Nano"},{"key":"967_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cell.2014.08.007","volume":"159","author":"MH Sherman","year":"2014","unstructured":"Sherman MH, Ruth TY, Engle DD, Ding N, Atkins AR, Tiriac H, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159:80\u201393.","journal-title":"Cell"},{"key":"967_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/gut.2005.064543","volume":"55","author":"JA McCarroll","year":"2006","unstructured":"McCarroll JA, Phillips PA, Santucci N, Pirola RC, Wilson J, Apte M. Vitamin A inhibits pancreatic stellate cell activation: implications for treatment of pancreatic fibrosis. Gut. 2006;55:79\u201389.","journal-title":"Gut"},{"key":"967_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14728222.2021.1857727","volume":"25","author":"Y Yu","year":"2021","unstructured":"Yu Y, Schuck K, Friess H, Kong B. Targeting aggressive fibroblasts to enhance the treatment of pancreatic cancer. Expert Opin Ther Targets. 2021;25:5\u201313.","journal-title":"Expert Opin Ther Targets"},{"key":"967_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74368-3","volume":"10","author":"L Gorchs","year":"2020","unstructured":"Gorchs L, Ahmed S, Mayer C, Knauf A, Fern\u00e1ndez Moro C, Svensson M, et al. The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity. Sci Rep. 2020;10:17444.","journal-title":"Sci Rep"},{"key":"967_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1432-0436.2006.00131.x","volume":"75","author":"N Pend\u00e1s-Franco","year":"2007","unstructured":"Pend\u00e1s-Franco N, Gonz\u00e1lez-Sancho JM, Su\u00e1rez Y, Aguilera O, Steinmeyer A, Gamallo C, et al. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation. 2007;75:193\u2013207.","journal-title":"Differentiation"},{"key":"967_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03225-9","volume":"9","author":"D Chen","year":"2018","unstructured":"Chen D, Xie J, Fiskesund R, Dong W, Liang X, Lv J, et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat Commun. 2018;9:873.","journal-title":"Nat Commun"},{"key":"967_CR15","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1111\/liv.15915","volume":"44","author":"LS Hou","year":"2024","unstructured":"Hou LS, Zhai XP, Zhang YW, Xing JH, Li C, Zhou SY. et al. Targeted inhibition of autophagy in hepatic stellate cells by hydroxychloroquine: an effective therapeutic approach for the treatment of liver fibrosis. Liver Int. 2024;44:1937\u201351.","journal-title":"Liver Int"},{"key":"967_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbrc.2022.04.058","volume":"610","author":"D Li","year":"2022","unstructured":"Li D, Yu K, Feng F, Zhang Y, Bai F, Zhang Y, et al. Hydroxychloroquine alleviates renal interstitial fibrosis by inhibiting the PI3K\/Akt signaling pathway. Biochem Biophys Res Commun. 2022;610:154\u201361.","journal-title":"Biochem Biophys Res Commun"},{"key":"967_CR17","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1158\/1078-0432.CCR-19-4042","volume":"26","author":"HJ Zeh","year":"2020","unstructured":"Zeh HJ, Bahary N, Boone BA, Singhi AD, Miller-Ocuin JL, Normolle DP, et al. A randomized phase II preoperative study of autophagy inhibition with high-dose hydroxychloroquine and gemcitabine\/nab-paclitaxel in pancreatic cancer patients. Clin Cancer Res. 2020;26:3126\u201334.","journal-title":"Clin Cancer Res"},{"key":"967_CR18","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/cells13221917","volume":"13","author":"YP Mayasin","year":"1917","unstructured":"Mayasin YP, Osinnikova MN, Kharisova CB, Kitaeva KV, Filin IY, Gorodilova AV. et al. Extracellular matrix as a target in melanoma therapy: from hypothesis to clinical trials. Cells. 1917;13:1917","journal-title":"Cells"},{"key":"967_CR19","doi-asserted-by":"publisher","first-page":"101881","DOI":"10.1016\/j.xcrm.2024.101881","volume":"6","author":"GP Nagaraju","year":"2025","unstructured":"Nagaraju GP, Saddala MS, Foote JB, Khaliq AM, Masood A, Golivi Y. et al. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Cell Rep Med. 2025;6:101881","journal-title":"Cell Rep Med"},{"key":"967_CR20","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, Cid RP, Chandana SR, De La Fouchardi\u00e8re C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402:1272\u201381.","journal-title":"Lancet"},{"key":"967_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-5-20","volume":"5","author":"PM De Angelis","year":"2006","unstructured":"De Angelis PM, Svendsrud DH, Kravik KL, Stokke T. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 2006;5:1\u201325.","journal-title":"Mol Cancer"},{"key":"967_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2021.12147","volume":"24","author":"R Xu","year":"2021","unstructured":"Xu R, Zhang Y, Li A, Ma Y, Cai W, Song L, et al. LY\u2011294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K\/AKT\/HIF\u20111\u03b1 pathway. Mol Med Rep. 2021;24:1\u201311.","journal-title":"Mol Med Rep"},{"key":"967_CR23","doi-asserted-by":"publisher","DOI":"10.7717\/peerj-cs.67","volume":"2","author":"J Anaya","year":"2016","unstructured":"Anaya J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput Sci. 2016;2:e67.","journal-title":"PeerJ Comput Sci"},{"key":"967_CR24","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3892\/mmr.2014.2008","volume":"9","author":"L Gao","year":"2014","unstructured":"Gao L, Shen L, Yu M, Ni J, Dong X, Zhou Y, et al. Colon cancer cells treated with 5\u2011fluorouracil exhibit changes in polylactosamine\u2011type N\u2011glycans. Mol Med Rep. 2014;9:1697\u2013702.","journal-title":"Mol Med Rep"},{"key":"967_CR25","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/1535-7163.MCT-08-1135","volume":"8","author":"KA Lewis","year":"2009","unstructured":"Lewis KA, Lilly KK, Reynolds EA, Sullivan WP, Kaufmann SH, Cliby WA. Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin. Mol Cancer Ther. 2009;8:855\u201363.","journal-title":"Mol Cancer Ther"},{"key":"967_CR26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1200\/JCO.2017.74.9564","volume":"36","author":"SR Hingorani","year":"2018","unstructured":"Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2018;36:359\u201366.","journal-title":"J Clin Oncol"},{"key":"967_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00681-z","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju Y, Xu D, Liao M-m, Sun Y, Bao W-D, Yao F, et al. Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol. 2024;8:199.","journal-title":"NPJ Precis Oncol"},{"key":"967_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01151-3","volume":"19","author":"J-q Fan","year":"2020","unstructured":"Fan J-q, Wang M-F, Chen H-L, Shang D, Das JK, Song J. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Mol Cancer. 2020;19:32.","journal-title":"Mol Cancer"},{"key":"967_CR29","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","volume":"3","author":"AN Hosein","year":"2022","unstructured":"Hosein AN, Dougan SK, Aguirre AJ, Maitra A. Translational advances in pancreatic ductal adenocarcinoma therapy. Nat Cancer. 2022;3:272\u201386.","journal-title":"Nat Cancer"},{"key":"967_CR30","doi-asserted-by":"publisher","first-page":"6823","DOI":"10.1002\/cam4.4216","volume":"10","author":"X Jiang","year":"2021","unstructured":"Jiang X, Wang J, Wang M, Xuan M, Han S, Li C, et al. ITGB4 as a novel serum diagnosis biomarker and potential therapeutic target for colorectal cancer. Cancer Med. 2021;10:6823\u201334.","journal-title":"Cancer Med"},{"key":"967_CR31","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/labinvest.2015.82","volume":"95","author":"RL Stewart","year":"2015","unstructured":"Stewart RL, O\u2019connor KL. Clinical significance of the integrin \u03b16\u03b24 in human malignancies. Lab Investig. 2015;95:976\u201386.","journal-title":"Lab Investig"},{"key":"967_CR32","first-page":"4326","volume":"12","author":"S Ko","year":"2022","unstructured":"Ko S, Jung KH, Yoon Y-C, Han BS, Park MS, Lee YJ, et al. A novel DDR1 inhibitor enhances the anticancer activity of gemcitabine in pancreatic cancer. Am J Cancer Res. 2022;12:4326.","journal-title":"Am J Cancer Res"},{"key":"967_CR33","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/labinvest.2014.166","volume":"95","author":"Y Masugi","year":"2015","unstructured":"Masugi Y, Yamazaki K, Emoto K, Effendi K, Tsujikawa H, Kitago M, et al. Upregulation of integrin \u03b24 promotes epithelial\u2013mesenchymal transition and is a novel prognostic marker in pancreatic ductal adenocarcinoma. Lab Investig. 2015;95:308\u201319.","journal-title":"Lab Investig"},{"key":"967_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2023.123155","volume":"303","author":"H Wang","year":"2023","unstructured":"Wang H, Rao P, Qiu Y, Xiang L. Interaction mechanism between hydroxychloroquine sulfate and collagen: Insights from multi-spectroscopy, molecular docking, and molecular dynamic simulation methods. Spectrochim Acta A Mol Biomol Spectrosc. 2023;303:123155.","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"967_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.matbio.2021.01.003","volume":"100","author":"F Migneault","year":"2021","unstructured":"Migneault F, H\u00e9bert M-J. Autophagy, tissue repair, and fibrosis: a delicate balance. Matrix Biol. 2021;100:182\u201396.","journal-title":"Matrix Biol"},{"key":"967_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep40464","volume":"7","author":"X-L Li","year":"2017","unstructured":"Li X-L, Liu L, Li D-D, He Y-P, Guo L-H, Sun L-P, et al. Integrin \u03b24 promotes cell invasion and epithelial-mesenchymal transition through the modulation of Slug expression in hepatocellular carcinoma. Sci Rep. 2017;7:40464.","journal-title":"Sci Rep"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00967-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00967-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00967-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T23:02:21Z","timestamp":1765753341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00967-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["967"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00967-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6406693\/v1","asserted-by":"object"}]},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The University of Alabama at Birmingham Institutional Animal Care permissions approved animal studies. The animal work was conducted under the protocol UAB-IUCAC-22541. This study meets the standards of animal ethics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}